Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Blood-based NfL - A biomarker for differential diagnosis of parkinsonian disorder
Neurol 88:930-937,922, Hansson, O.,et al, 2017
Early Weight Loss in Parkinsonism Predicts Poor Outcomes
Neurol 89:2254-2261, Cumming, K.,et al, 2017
Parkinsons Disease Beyond 20 Years
JNNP 86:849-855, Cilia, R.,et al, 2015
Long-Term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease Implications for the Future of Cell Therapy
JAMA 311:617-618, Bega, D. & Krainc, D., 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
A Meta-Regression of the Long-Term Effects of Deep Brain Stimulation on Balance and Gait in PD
Neurol 75:1292-1299, St. George,R.J.,et al, 2010
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Dementia and Survival in Parkinson Disease: A 12-Year Population Study
Neurol 70:1017-1022, Buter,T.C.,et al, 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Serum Uric Acid and Clinical Progression in Parkinson Disease: Potential Biomarker for Nigrostriatal Failure
Arch Neurol 65:698-699, Schiess,M. &Oh,I., 2008
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Is DBS-STN Appropriate to Treat Severe Parkinson Disease in an Elderly Population?
Neurol 68:1345-1355, Derost,P.-P.,et al, 2007
Benign Tremulous Parkinsonism
Arch Neurol 63:354-357,321, Josephs,K.A.,et al, 2006
Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review)
Neurol 66:968-975, Suchowersky,O.,et al, 2006
A Randomized Trial of Deep-Brain Stimulation for Parkinsons Disease
NEJM 355:896-908, Deuschl,G.,et al, 2006
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Post-Stroke Movement Disorders; Report of 56 Patients
JNNP 75:1568-1574, Alarcon,F.,et al, 2004
Parkinson Disease With Old-Age Onset
Arch Neurol 60:529-533, Diederich,N.J.,et al, 2003
Five-Year Follow-up of Bilateral Stimulatioin of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 349:1925-1934,1888, Krack,P.,et al, 2003
Long-Term Follow-Up of Thalamic Deep Brain Stimulation for Essential and Parkinsonian Tremor
Neurol 61:1601-1604, Kumar,R.,et al, 2003
Bilateral Subthalamic Nucleus Stimulation Improves Health-Related Quality of Life in PD
Neurol 59:1976-1978, Lagrange,E.,et al, 2002
Deep Brain Stimulation in the Treatment of Parkinson's Disease,A Cost-Effectiveness Analysis
Neurol 57:663-671, Tomaszewski,K.J.&Holloway,R.G., 2001
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Long-Term Follow-Up of Unilateral Pallidotomy in Advanced Parkinson's Disease
NEJM 342:1708-1714, Fine,J.,et al, 2000
Health-Related Quality of Life in Neurology
Arch Neurol 57:1224-1227, Meyers,A.R. et al, 2000
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Selegiiline and Mortality in Subjects with Parkinson's Disease
Neurol 55:1785-1789,1770, Donnan,P.T.,et al, 2000
Progression of Parkinsonian Signs in Parkinson Disease
Arch Neurol 56:334-337, Louis,E.D.,et al, 1999
Mortality Cancer Risk in Parkinsonian Patients:A Population-Based Study
Neurol 52:395-398, Vanacore,N.,et al, 1999
Long-Term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Arch Neurol 56:179-187, Hauser,R.A.,et al, 1999
Unilateral Pallidotomy for Parkinson's Disease:Results after More Than 1 Year
JNNP 67:511-517, Schrag,A.,et al, 1999
Natural History & Survival of 14 Pts with Corticobasal Degeneration Confirmed as Postmortem Exam
JNNP 64:184-189, Wenning,G.K.,et al, 1998
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Hereditary Form of Parkinsonism-Dementia
Ann Neurol 43:768-781, Muenter,M.D.,et al, 1998
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Effect of Selegiline on Mortality in Patients with Parkinson's Disease
Neurol 51:825-830, Olanow,C.W.,et al, 1998
Surgery for Parkinson's Disease
JNNP 62:2-8, Obeso,J.A.,et al, 1997
Mortality from Parkinson Disease
Arch Neurol 54:260-264, Louis,E.D.,et al, 1997
Clinical Characteristics of a Chromosome 17-Linked Rapidly Progressive Familial Frontotemporal Dementia
Arch Neurol 54:539-544, Basun,H.,et al, 1997
Stereotactic Pallidotomy for Parkinson's Disease:A Long-Term Follow-up of Unilateral Pallidotomy
Neurol 48:1273-1277, Fazzini,E.,et al, 1997
Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
NEJM 334:71-76, Bennett,D.A.,et al, 1996
Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996
Survival & Prolif of Nonneural Tissu, with Obstr of Cereb Ventric, In Parkinson Pt Trt with Fetal Allografts
Neurol 46:1219-1225, Folkerth,R.D.&Durso,R., 1996